| Literature DB >> 36157422 |
Hugo Clermidy1, Guillaume Fadel1, Alexandra De Lemos1, Pauline Pradere2, Delphine Mitilian1, Antoine Girault1, Jean-Baptiste Menager1, Dominique Fabre1, Sacha Mussot1, Nicolas Leymarie3, Elie Fadel1, Olaf Mercier1.
Abstract
Objectives: En-bloc complete resection remains the treatment of choice for localized chest wall (CW) tumors. Titanium bars reconstruction demonstrated encouraging results with satisfactory early outcomes. However, long-term outcomes remain under-reported. The purpose of this study is to evaluate long-term outcomes after CW resection and repair with titanium devices.Entities:
Keywords: chest wall resection; fracture; infection; long term; titanium bars
Year: 2022 PMID: 36157422 PMCID: PMC9489911 DOI: 10.3389/fsurg.2022.950177
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Flow chart of the study.
Figure 2Operative field pictures showing: (A) Thorib® bar for lateral chest wall reconstruction with vicryl mesh interposition and pedicled homolateral latissimus dorsi flap. (B) Trionyx® sternal plate reconstruction after total sternectomy covered by homolateral latissimus dorsi pedicled flap. (C) Thorib® bar reconstruction after manubrial resection. (D) Thorib® bar crossing the midline and attached to the contralateral rib.
Figure 3Postoperative chest x-rays after (A) Thorib® bar interposition and (B) Trionyx® sternal reconstruction.
Patients’ characteristics.
| All | Thorib | Trionyx | ||||
|---|---|---|---|---|---|---|
|
| 68 | 51 | 17 | |||
| Age | ||||||
| Median, range | 56.5 | 18–80 | 57.3 | 18–80 | 50 | 18–80 |
| Follow-up | ||||||
| Mean (months, range, SD) | 43.2 | (2.9–100.1); 30 | 40.3 | (2.9–100.1); 31.0 | 52 | (11.1–93.7); 27.2 |
| Gender [ | ||||||
| Male | 26 | 38% | 21 | 41% | 5 | 29% |
| Female | 42 | 62% | 30 | 59% | 12 | 71% |
| Co-morbidity | ||||||
| BMI (mean) (kg/m2) | 24.8 | 24.1 | 27 | |||
| Diabetes [ | 5 | 7% | 4 | 8% | 1 | 6% |
| Smoking history [ | 25 | 37% | 20 | 39% | 5 | 29% |
| Pack-year (mean) | 9.8 | (0–60) | 11.5 | (0–60) | 5 | (0–30) |
| Preoperative FVC (%, range) | 101 | (62–144) | 102 | (62–144) | 99 | (68–138) |
| Preoperative FEV1 (%, range) | 96 | (58–140) | 96 | (53–140) | 96 | (66–132) |
| Pathology | ||||||
| Primary tumor [ | 48 | 71% | 42 | 82% | 6 | 35% |
| Sarcoma | 30 | 44% | 26 | 51% | 4 | 24% |
| Lung carcinoma | 8 | 12% | 8 | 16% | 0 | 0% |
| Breast carcinoma | 4 | 6% | 3 | 6% | 1 | 6% |
| Thymoma or thymic carcinoma | 3 | 4% | 2 | 4% | 1 | 6% |
| Sarcomatoid mesothelioma | 2 | 3% | 2 | 4% | 0 | 0% |
| Desmoid tumor | 1 | 1% | 1 | 2% | 0 | 0% |
| Metastatic tumors [ | 20 | 29% | 9 | 18% | 11 | 65% |
| Breast | 12 | 18% | 5 | 10% | 7 | 41% |
| Sarcoma | 3 | 4% | 2 | 4% | 1 | 6% |
| Colon | 1 | 1% | 1 | 2% | 0 | 0% |
| Liver | 1 | 1% | 0 | 0% | 1 | 6% |
| Larynx | 1 | 1% | 1 | 2% | 0 | 0% |
| Parotid | 1 | 1% | 0 | 0% | 1 | 6% |
| Kidney | 1 | 1% | 0 | 0% | 1 | 6% |
BMI, body mass index; FVC, forced vital capacity; FEV1, first second of forced expiration.
Early and late outcomes after chest wall reconstruction using titanium.
| All | Thorib | Trionyx | |||||
|---|---|---|---|---|---|---|---|
|
| 68 | 51 | 17 | ||||
| Infection | 12 | 18% | 9 | 18% | 3 | 18% | 1 |
| Early | 11 | 16% | 8 | 16% | 3 | 18% | 1 |
| Late | 1 | 1% | 1 | 2% | 0 | 0% | 1 |
| Implant failure | 4 | 6% | 3 | 6% | 1 | 6% | 1 |
| Chronic pain | 16 | 24% | 10 | 20% | 6 | 35% | 0.20 |
| Titanium allergy | 0 | 0% | 0 | 0% | 0 | 0% | 1 |
| Respiratory failure | 6 | 9% | 6 | 12% | 0 | 0% | 0.32 |
| Bar or plate removal | 7 | 10% | 7 | 14% | 0 | 0% | 0.18 |
| Reoperation without removal of the bars or plate | 6 | 9% | 3 | 6% | 3 | 18% | 0.16 |
Figure 4Survival and recurrence of the study population: (A) Overall survival of the whole cohort. (B) Freedom from recurrence of the whole cohort. (C) Overall survival according to the type of titanium reconstruction (Thorib® or Trionyx®). (D) Overall survival according to the completeness of resection. (E) Overall survival according to the primitive or metastatic nature of the tumor. (F) Overall survival according to the tumor's histopathology. (G) Overall survival according to the presence of surgical site infection. (H) Overall survival according to the presence of implant failure.
Figure 5Long-term respiratory function before and after chest wall tumor resection and repair. (A) Forced vital capacity (FVC) before surgery and after surgery (≥3 months). (B) First second of forced expiration (FEV1) before surgery and after surgery (≥3 months).